On May 23, 2023 ImmPACT Bio USA, Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, reported that it will participate at the 2023 Jefferies Healthcare Conference, to be held from June 7-9, 2023, in New York, NY (Press release, ImmPACT-Bio, MAY 23, 2023, View Source [SID1234631979]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio’s president and chief executive officer, will provide a corporate update and participate in a live Q&A session on Wednesday, June 7, 2023, at 2:00 PM ET. A live webcast of the presentation can be accessed at https://bit.ly/3Mhkkdv.